维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

交易中 08-11 13:07:15

66.800

+0.400

+0.60%

最高67.800	最低65.300	成交量96.26万
今开67.000	昨收66.400	日振幅3.77%
总市值132.93亿	流通市值132.26亿	总股本1.99亿
成交额6,406万	换手率0.49%	流通股本1.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":66.8,"timestamp":1786424823902,"preClose":66.4,"halted":0,"volume":962600,"delay":0,"changeRate":0.00602409638554204,"floatShares":198000000,"shares":199000000,"eps":-1.407324917225038,"marketStatus":"交易中","change":0.4,"latestTime":"08-11 13:07:15","open":67,"high":67.8,"low":65.3,"amount":64058505,"amplitude":0.037651,"askPrice":67,"askSize":1200,"bidPrice":66.75,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.368943328573446,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1786435800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":66.4,"openAndCloseTimeList":[[1786411800000,1786420800000],[1786424400000,1786435200000]],"volumeRatio":1.036771,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"2657633026","title":"南京礼至企业管理咨询中心(有限合伙)减持维立志博-B(09887.HK)31.29万股 每股作价约53.81港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633026","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657633026?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:22","pubTimestamp":1786015331,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657450310","title":"港股异动 | 维立志博-B(09887.HK)涨超3% 维利信™一线治疗肝细胞癌Ⅱ期临床研究顺利进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2657450310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657450310?lang=zh_cn&edition=full","pubTime":"2026-08-06 10:19","pubTimestamp":1785982797,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145087257","title":"维立志博-B Opamtistomig（PD-L1/4-1BB双特异性抗体）一线肝细胞癌治疗获阳性疗效信号，推进至扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1145087257","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145087257?lang=zh_cn&edition=full","pubTime":"2026-08-06 08:54","pubTimestamp":1785977664,"startTime":"0","endTime":"0","summary":"维立志博-B（LEADS BIOLABS-B）近日宣布，其研发的Opamtistomig（PD-L1/4-1BB双特异性抗体）在一线肝细胞癌（HCC）治疗中传出积极疗效信号。基于这一鼓舞人心的数据，该药物已正式迈入临床研究的扩展阶段。这一进展不仅为肝癌患者带来了新希望，也标志着公司在肿瘤免疫治疗领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571068","title":"维立志博-B(09887)：维利信™用于治疗肝细胞癌的Ⅱ期研究顺利进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657571068?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:17","pubTimestamp":1785968230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，本公司自主研发的PD-L1/4-1BB双特异性抗体奥帕替苏米单抗(维利信)一线治疗肝细胞癌Ⅱ期临床研究经专家审议完成安全性导入期评估，顺利进入扩展阶段。HCC起病隐匿，首次诊断时只有不到30%的患者适合接受根治性治疗，系统抗肿瘤治疗在中晚期HCC的治疗过程中发挥重要的作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：维利信™用于治疗肝细胞癌的Ⅱ期研究顺利进入扩展阶段","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","09887","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555988","title":"左鸿刚增持维立志博-B(09887.HK)3500股 每股作价53.16港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656555988?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:57","pubTimestamp":1785844678,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177394211","title":"维立志博合作伙伴Oblenio Bio宣布：Lbl-051治疗难治性自身免疫疾病1a期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1177394211","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177394211?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:57","pubTimestamp":1785844629,"startTime":"0","endTime":"0","summary":"维立志博-B（09887.HK）的合作伙伴Oblenio Bio今日宣布，针对难治性自身免疫疾病的候选药物Lbl-051已在其1a期临床试验中完成首例患者给药。这一里程碑标志着该潜在疗法从实验室走向临床的关键一步，为那些对现有治疗手段反应不佳的患者群体带来了新希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","09887","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558888","title":"维立志博-B(09887.HK)：合作方OBLENIO完成LBL-051在难治性自身免疫疾病中的IA期临床试验首批患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558888","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656558888?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:07","pubTimestamp":1785841663,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130917441","title":"维立志博-B：LBL-051欧洲Ia期临床实现首例给药 并披露关联激励安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1130917441","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130917441?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:06","pubTimestamp":1785841572,"startTime":"0","endTime":"0","summary":"2026年8月4日，维立志博-B发布自愿性公告称，其与Aditum Bio共同设立的美国公司Oblenio Bio Inc.已在欧洲开展的LBL-051 Ia期首个人体临床试验中完成首批患者给药，标志项目进入实际临床验证阶段。维立志博-B凭借自主LeadsBodyTM平台负责LBL-051的发现与设计，并将继续为Oblenio提供技术支持。公司提醒股东及潜在投资者，依据《上市规则》第18A.05条规定，LBL-051能否成功开发及最终上市尚存在不确定性；投资者买卖公司股份时需审慎行事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656533588","title":"【券商聚焦】浙商证券首予维立志博（09887）买入评级 指核心产品商业化迎跃迁","url":"https://stock-news.laohu8.com/highlight/detail?id=2656533588","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656533588?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:15","pubTimestamp":1785827729,"startTime":"0","endTime":"0","summary":"研报核心逻辑聚焦于公司核心产品LBL-024的商业化与临床数据催化。浙商证券预计公司2026-2028年营业收入分别为284、395、756百万元，2026-2028年营收同比增速分别为60%、39%、91%；2026-2028年公司归母净利润分别为-203、-211、-51百万元，首次覆盖，给予“买入”投资评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","KCE","601878"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175109062","title":"维立志博-B7月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1175109062","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175109062?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:38","pubTimestamp":1785746332,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司于2026年8月3日发布截至2026年7月31日止的证券变动月报表。其中，香港联交所上市的H股数量为197,670,289股，未上市股份数量为1,221,511股，较上月均保持不变。公告提到，2026年7月1日，公司依据2025年12月17日股东大会批准的H股奖励计划，已向149名受让人授出合计2,254,691份奖励，并列示该计划在本月底可能继续发行或自库存转让的股份数量为9,944,590股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159773638","title":"维立志博PD-L1/4-1BB双抗联合疗法获准用于转移性结直肠癌，消化道肿瘤管线再添新翼","url":"https://stock-news.laohu8.com/highlight/detail?id=1159773638","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159773638?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:44","pubTimestamp":1785728649,"startTime":"0","endTime":"0","summary":"维立志博-B（LEADS BIOLABS-B）自主研发的PD-L1/4-1BB双特异性抗体，其针对转移性结直肠癌联合疗法的临床试验申请已获监管部门批准。这一进展，标志着公司在消化道肿瘤领域的布局又迈出坚实一步，使得其肿瘤免疫治疗管线愈发厚实与多元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000252160.HKD","BK1161","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656341613","title":"维立志博：维利信治疗结直肠癌IND获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2656341613","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656341613?lang=zh_cn&edition=full","pubTime":"2026-08-03 09:11","pubTimestamp":1785719460,"startTime":"0","endTime":"0","summary":"8月3日，维立志博（09887）发布公告，公司自主研发PD-L1/4-1BB双特异性抗体维利信（奥帕替苏米单抗，LBL-024）治疗转移性结直肠癌的IND申请获CDE批准，将开展开放标签、多中心Ib/II期临床，评估联合用药的安全性与有效性。此次获批推动该药物拓展消化道肿瘤适应症，公司免疫治疗管线覆盖癌种延伸至结直肠癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829261864.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829261864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09887","IND","BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656349931","title":"维立志博-B(09887.HK)转仓市值总计3.64亿港元 占比3.62% 从中国证券登记结算香港转出406.94万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656349931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656349931?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:45","pubTimestamp":1785717955,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252152.HKD","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178807804","title":"维立志博-B（09887）自主研发双特异性抗体维利信™获国家药监局IND批准 用于转移性结直肠癌临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1178807804","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178807804?lang=zh_cn&edition=full","pubTime":"2026-08-03 06:11","pubTimestamp":1785708664,"startTime":"0","endTime":"0","summary":"2026年8月3日，维立志博-B发布自愿公告称，其自主研发的PD-L1/4-1BB双特异性抗体奥帕替苏米单抗已获中国国家药品监督管理局药品审评中心批准，用于治疗转移性结直肠癌的新药临床试验申请。本次新增mCRC适应症，标志着公司免疫治疗布局进一步覆盖结直肠癌领域。中国国家癌症中心数据显示，2022年中国新发结直肠癌约517,000例，死亡约240,000例，在恶性肿瘤中发病率和死亡率分别位居第2位和第4位。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656459983","title":"维立志博-B(09887.HK)：维利信™获国家药监局IND批准用于治疗转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2656459983","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656459983?lang=zh_cn&edition=full","pubTime":"2026-08-03 06:10","pubTimestamp":1785708645,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164403377","title":"异动解读｜维立志博-B盘中上涨5.11%，核心管线胆道癌II期研究完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1164403377","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164403377?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:02","pubTimestamp":1785463363,"startTime":"0","endTime":"0","summary":"7月31日，维立志博-B盘中上涨5.11%，报52.65港元，成交额3700.08万港元。消息面上，公司7月30日公告，其核心在研药物维利信用于一线治疗晚期胆道癌的II期临床研究已完成全部70例患者入组。该项目于4月基于良好安全性与超预期疗效数据进入扩展阶段后迅速完成入组，体现高效临床推进速度。此前维利信已获国家药监局纳入优先审评审批程序，商业化时间表正式锁定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维立志博-B盘中上涨5.11%，核心管线胆道癌II期研究完成全部患者入组","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655038723","title":"维立志博-B(09887)转仓市值总计3.46亿港元占比3.39% 从中国证券登记结算香港转出561.20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655038723","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655038723?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:20","pubTimestamp":1785457250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月30日，维立志博-B出现仓位异动，转仓市值总计3.46亿港元，占比3.39%。该公司股东向摩根士丹利香港证券转入298.59万股，从中国证券登记结算香港转出561.20万股。维立志博7月24日公布，公司近期收到集团联合创始人、公司董事长、执行董事、首席执行官兼总经理康小强博士的承诺通知，内容有关自愿延长其直接持有全部7,874,617股H股的禁售期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","161027","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139802607","title":"维立志博-B Opamtistomig（PD-L1/4-1BB双特异性抗体）胆道癌II期研究完成患者入组，进一步展现免疫冷肿瘤突破性潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1139802607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139802607?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:39","pubTimestamp":1785407953,"startTime":"0","endTime":"0","summary":"维立志博-B今日宣布，其核心在研药物Opamtistomig针对胆道癌的II期临床研究已顺利完成全部患者入组。这一里程碑事件，不仅标志着该药物在免疫冷肿瘤领域的探索迈出关键一步，更显著强化了其作为潜在突破性疗法的市场预期。若最终结果积极，Opamtistomig有望成为全球范围内首个针对胆道癌的PD-L1/4-1BB双抗类药物，为这一难治性肿瘤患者群体带来全新治疗选择。市场分析人士指出，维立志博在双特异性抗体领域的持续深耕，正逐步兑现其技术平台的临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655873608","title":"维立志博-B：奥帕替苏米单抗用于治疗胆道癌的Ⅱ期临床研究完成70例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2655873608","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655873608?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:20","pubTimestamp":1785406800,"startTime":"0","endTime":"0","summary":"7月30日，维立志博-B（09887）发布公告，奥帕替苏米单抗（维利信，一款PD-L1/4-1BB双特异性抗体，LBL-024）用于治疗晚期胆道癌的Ⅱ期临床研究已完成全部70例患者入组。该项目于2026年4月基于良好的安全性与超出预期的疗效数据顺利进入扩展阶段，迅速完成患者入组，体现了维利信的高效临床推进速度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826839224.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826839224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134438272","title":"维立志博-B（09887）公布维利信™用于晚期胆道癌Ⅱ期临床试验完成70例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1134438272","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134438272?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:51","pubTimestamp":1785405112,"startTime":"0","endTime":"0","summary":"2026年7月30日，维立志博-B（09887）公告，其PD-L1/4-1BB双特异性抗体维利信™（奥帕替苏米单抗，代号 LBL-024）用于一线治疗晚期胆道癌（BTC）的Ⅱ期临床研究已完成全部70例患者入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":0.1659},{"period":"1month","weight":0.3301},{"period":"3month","weight":-0.1194},{"period":"6month","weight":0.0993},{"period":"1year","weight":-0.0342},{"period":"ytd","weight":0.302}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0729},{"period":"3month","weight":-0.0156},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.0434},{"period":"ytd","weight":0.012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}